Improvement of Humoral Immune Response With Hemodialysis on BK-F Membrane: Correlation to Soluble CD40 Clearing

Summary

The aim of this study is to improve the humoral immune response efficiency of hemodialyzed patient by the use of PMMA membrane (BK-F) able to clear the soluble form of CD40 in a model of anti-HBV vaccination

Conditions

• Chronic Renal Failure
• Humoral Immune Alterations

Interventions

PROCEDURE

High flux polymethylmetacrylate membrane

Patients will be hemodialysed with high flux polymethylmetacrylate membranes

PROCEDURE

Polysulfone membrane

Patients be hemodialysed with polysulfone membranes

BIOLOGICAL

Hepatitis B serological control

It will be assessed at week 16, week 20 and week 40

BIOLOGICAL

Seric sCD40 level

Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.

Sponsors & Collaborators

• University Hospital, Bordeaux

  lead OTHER

Principal Investigators

• Valérie de PRECIGOUT, MD · University Hospital, Bordeaux, France

• Pierre BORIES, MD · University Hospital, Toulouse, France

• Michel RINCE, MD · University Hospital, Limoges, France

• Caroline DELCLAUX, MD · Hospital, Libourne, France

• Antoine POMMEREAU, MD · Clinic Saint-Augustin, Bordeaux, France

• Benjamin DEROURE, MD · Clinic Delay, Bayonne, France

• Hervé BONAREK, MD · Hospital, Saintes, France

• Antoine BENARD, MD · University Hospital, Bordeaux, France

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-04-30

Primary Completion

2015-01-31

Completion

2015-01-31

Countries

• France

Study Locations